• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

Imugene Share Price Lifts as Fresh Results Show Promise (ASX:IMU)

Like 0

By Ryan Clarkson-Ledward, Monday, 23 November 2020

The Imugene Ltd [ASX:IMU] share price is trading 15% higher at time of writing. Rising on the back of new news from the biotech’s phase 2 trial. In what is now just the latest leg up for the company in the past month...

The Imugene Ltd [ASX:IMU] share price is trading 15% higher at time of writing. Rising on the back of new news from the biotech’s phase 2 trial. In what is now just the latest leg up for the company in the past month.

Since early November the Imugene share price has doubled. Climbing from 6 cents per share just over two weeks ago to 12 cents today.

Let’s delve into the data behind this latest find.

Positive findings

According to Imugene, interim analysis from their ongoing Phase 2 trial has generated some noteworthy results.

The biotech has been working on a potential treatment for gastric cancer. Experimenting with a novel protein known as HER-2, which may be linked to the disease.

What the company shared today though, was insight into their HER-Vaxx drug. Finding that patients who received this treatment, alongside chemotherapy, reported greater survival rates. With the average time recorded of 14.2 months, compared to just 8.8 months on chemo alone.

Obviously, that is a fantastic result. Giving these patients more precious time.

Plus, the committee overseeing the study has reported no safety concerns whatsoever. Suggesting that the drug is in fact not only working, but also completely safe for patient use.

Keep in mind though, this is not yet a final ruling or conclusion on HER-Vaxx’s effectiveness.

Imugene’s CEO Leslie Chong was notably pleased:

‘I am delighted to report that we have achieved this significant milestone for patients with advanced gastric cancer. I am excited that the interim analysis favoured the survival outcome for HER-Vaxx and the IDMC suggested to shorten the study by lowering the number of patients.

‘This data represents a clinical proof-of-concept for HER-Vaxx and supports our B-cell activating immunotherapy platform. I look forward to updating the market as the data matures.’

What’s next for the Imugene share price?

For shareholders the wait is now on for this phase 2 trial to come to an end. Hopefully with final results that are just as good or better than today’s.

Then, from there, Imugene will likely need to proceed with a further Phase 3 trial; the last step before any possibility of bringing the drug to market.

But, with today’s news, they are at least one step closer to that goal.

Regards,

Ryan Clarkson-Ledward,
For Money Morning

PS: For more share market news and analysis, check out our daily Money Morning e-letter. Bringing you the latest and most important investing tips you won’t find anywhere else. Click here to find out more.

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Ryan Clarkson-Ledward

Ryan’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • The US$2 Trillion Stablecoin Tsunami
    By Charlie Ormond

    These developments could transform the US$250 billion stablecoin market into a US$2 trillion juggernaut within years.

  • Trump Sparks Rare Earth Rally
    By Murray Dawes

    Murray and Callum pointed out three lithium stocks last week that surged 5–12% this week. Now they look at copper and rare earths.

  • Copper Breaks Out: Are You Positioned?
    By James Cooper

    Last week, James Cooper wrote about the need to be on high alert for a copper breakout. This week, copper is breaking out… James lays out the game plan from here.

Primary Sidebar

Latest Articles

  • The US$2 Trillion Stablecoin Tsunami
  • Trump Sparks Rare Earth Rally
  • Copper Breaks Out: Are You Positioned?
  • A radically innovative industry set to soar
  • Debt and declining demographics are a dangerous combination

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988